Abstract: A self-reinforcing composite gel includes a solvent, and a plurality of swellable crosslinked polymer particles dispersed in a crosslinked polymer matrix, wherein the crosslinked polymer matrix and the plurality of swellable crosslinked polymer particles are immersed in the solvent, wherein the swellable crosslinked polymer particles absorb more solvent at equilibrium than the matrix polymer, and wherein the plurality of swellable crosslinked polymer particles swell in the solvent and are present in an amount sufficient to maintain or increase the elastic modulus and/or load-bearing ability of the self-reinforcing composite gel, i.e., compared to that of the crosslinked matrix polymer alone, upon swelling in the solvent.

Abstract: Esterquat compositions are disclosed that comprise, based on the weight of the composition, 0% to about 70% by weight of a solvent, and about 30% to 100% by weight of a mixture comprising about 50% to about 80% by weight, based on the weight of the mixture, of esterquats and about 20% to about 50% by weight, based on the weight of the mixture, of mono- and diglycerides. The esterquat compositions can be prepared by the direct esterification of a natural oil with an alkanolamine, followed by quaternization in the presence of the solvent. The esterquat compositions can be formulated into hair care compositions that provide improved wet and dry combing properties.

Abstract: A method of repairing oxidatively-treated hair, the methods comprising the sequential steps of: (i) soaking hair in an aqueous treatment composition, (ii) rinsing the hair of step (i); characterised in that the aqueous treatment composition comprises 0.1 to 6 wt % N-acetyl amino acid, based on the total weight of the composition, wherein the N-acetyl amino acid is selected from the group consisting of N-acetyl glycine, N-acetyl alanine, N-acetyl proline, N-acetyl leucine, N-acetyl isoleucine, N-acetyl valine, N-acetyl tyrosine, N-acetyl phenylalanine, N-acetyl tryptophan, N-acetyl serine, N-acetyl glutamine, N-acetyl threonine, N-acetyl asparagine, N-acetyl methionine, N-acetyl lysine, N-acetyl histidine and mixtures thereof, gives damage repair benefits.

Abstract: Methods of administering apoptotic compensatory proliferation signaling vesicles (AC PS Vs), and pharmaceutical formulations thereof, are described herein. AC PS Vs can be used to promote proliferation of cells in injured or diseased tissues, for example by adding a therapeutically effective amount of APCSVs to the injured or diseased tissue.

Abstract: One composite composition of the present invention contains: a silicon fine particle; and a silicon suboxide (SiOX, wherein x is ½, 1, or 3/2) and/or a mixed composition of the silicon suboxide and silicon dioxide, at least partially covering the surface of the silicon fine particle.

Abstract: The present invention relates to a solid phase pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and an active pharmaceutical ingredient (“API”) which is a compound of formula A1 or A2 or a pharmacologically acceptable salt, solvate or hydrate thereof, wherein the API is not exposed to a basic compound.

Abstract: An aerosol cosmetic composition is provided that includes an oil soluble gloss enhancing film forming component, a solvent, a colorant, a propellant, and useful for application to hair or skin. An aerosol dispensing system and a method of preparing an aerosol sprayable color composition are also provided.

Abstract: The present invention relates to methods of treating an auditory disorder. In particular, the present invention relates to treating an auditory disorder using supraparticles comprising a therapeutic payload.

Abstract: The present disclosure relates to the development of hydrogels with extreme stiffness and high-strength. In particular, an hydrogel comprising poly(2-hydroxyethyl methacrylate) and graphene material with a specific oxidation degree. The hydrogels of the present disclosure may be used in medicine, veterinary or cosmetic, namely as scaffold, cartilage, intervertebral disc and blood contact device such as: catheters, vascular grafts, heart valves, stents, artificial kidneys, artificial lungs, ventricular assist devices or drug delivery system. Uses in other areas can be envisaged, like in soft robotics, packaging, sealing and sensors.

Abstract: A composition for detoxifying insect pollinators from one or more organophosphate pesticides, the composition containing microparticles comprising: (i) a phosphotriesterase; (ii) nanoparticles; and (iii) a surface active agent. Also disclosed herein is an aqueous suspension comprising the above-described detoxifying microparticles in an external aqueous medium, which may also contain an insect pollinator attractant. Also described herein is a method for detoxifying insect pollinators of one or more organophosphate pesticides, the method comprising placing the detoxifying aqueous suspension in a location accessible to the insect pollinators to permit the insect pollinators to ingest the detoxifying aqueous suspension, wherein the detoxifying aqueous suspension comprises microparticles, as described above, suspended in an external aqueous medium, typically also including an insect pollinator attractant in the external aqueous medium.

Abstract: Embodiments of the disclosure relate generally to formulations, methods of treatment, kits, and dosage forms for treating inflammatory disorders, including topic dermatitis, cancer, the formulations comprising an active pharmaceutical ingredient. The formulation provided comprises granules, wherein the granules comprise: micronized active ingredient; one or more granulation binders; one or more fillers; one or more disintegrants; and one or more antioxidants. In one embodiment, the methods of treatment include orally administering the active ingredient to a subject suffering from atopic dermatitis, where the active ingredient, is in an amount of about 20 mg to about 80 mg.

Abstract: Compositions, processes, and methods are provided including, but not limited to, a composition including a plurality of clay nanoparticles, wherein each clay nanoparticle comprises an anionic component and a cationic component wherein the anionic component has the formula (I): [(Si8MgbLic)O20(OH)4]??(I) wherein 5.5<b?6, and wherein c>0 and b/c>12.

Abstract: Disclosed herein are methods of treating venous thrombosis and vascular inflammation through administration of carbon monoxide and/or a carbon monoxide releasing molecule. Also disclosed herein are devices capable of releasing carbon monoxide for the purpose of treating microvascular, arterial and venous thromboembolism and/or inflammation.

Abstract: The present application relates to magnesium picolinate compositions and methods of use. The methods and compositions disclosed herein are particularly useful for providing bioavailable magnesium to mammals and treating or preventing symptoms of magnesium deficiency.

Abstract: Suggested is a mixture comprising or consisting of: (a) a protein extract obtained from cereal gluten extracted by means of aqueous ethanol, said extract being characterized by a content of at least 50 wt.-% proteins having a molecular weight of at least 22 kDa; (b) at least one organic acid; and (c) at least one cosmetically acceptable carrier.

Abstract: The present specification relates to an adamantanecarboxylic acid benzyl amide derivative compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, and a skin whitening composition comprising the same as an active ingredient. Specifically, the compound, according to the present specification, is a compound having a novel structure having adamantanecarboxylic acid bound to an amine compound, and exhibits a skin whitening effect by inhibiting the production of melanin, and thus may be used in various ways as a pharmaceutical composition, a cosmetic composition or a skin preparation for external use.

Abstract: Compositions, specifically a jelly, are provided the use of which composition as an auxiliary means eases the taking of oral medication in solid form, which composition comprises iota-carrageenan as a jellifying agent and citric acid as a salivating agent, characterized in that the composition further comprises maltodextrin. In another aspect, the composition comprises a calcium sequestrant for adjusting Ca-ion activity of the composition. In one embodiment, the composition comprises iota-carrageenan in 0.7-1.0% in mass, citric acid in 0.06-0.07% in mass, maltodextrin in 1.5% in mass, all relative to the total mass of the composition, and an amount of a calcium sequestrant such that the Ca-ion activity of the composition is between 20 ppm and 80 ppm.

Abstract: Provided is a dry pad, including a wound-covering membrane formed by arranging a fiber containing a hydrophilic polymer that is swollen by an exudate secreted from a wound, a hydrophobic polymer, and a dry wound-healing agent that is released through swelling of the hydrophilic polymer and is difficult to store in a liquid phase, and a first release member, which is a support on which the fiber is arranged and which is separated from the wound-covering membrane.

Abstract: The present invention provides methods and taste-modifying kits for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The methods and taste-modifying kits can improve patient compliance, and thus, efficacy of the preparation. Specifically, the present methods make the gastrointestinal tract preparation composition palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation solution taste significantly less salty.

Abstract: A personal care composition is provided, comprising: a vehicle; a cosmetically acceptable oil; and a cationic polymer comprising structural units of acrylamide monomer; structural units of N,N-dimethyl acrylamide monomer; and structural units of monoethylenically unsaturated monocationic monomer; wherein the cationic polymer comprises <10 mol % structural units of multiethylenically unsaturated cationic monomer; wherein the cationic polymer comprises <30 wt % structural units of ester containing monomers; wherein the cationic polymer comprises <1 mol % structural units of ethylenically unsaturated monomers containing a moiety selected from the group consisting of epoxy, anhydride, imide, lactone, carboxylic acid, sulfonic acid and isocyanate; wherein the cationic polymer comprises <0.1 mol % structural units of a reactive siloxane; and wherein the personal care composition comprises <0.05 wt % water soluble, organic, ampholytic polymer conditioning agent.